cyclopentane has been researched along with Leukemia, Myelomonocytic, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adès, L; Anagnostopoulos, A; De Paz Arias, R; Díez-Campelo, M; Doronin, VA; Faller, DV; Fram, RJ; Friedlander, S; Girshova, L; Kambhampati, S; Munhoz, EC; Platzbecker, U; Santini, V; Sekeres, MA; Symeonidis, A; Valcárcel, D; Viniou, NA; Woszczyk, D; Yuan, Y | 1 |
| Adès, L; Bell, J; Campelo, MD; Cerrano, M; Faller, DV; Fram, RJ; Friedlander, S; Graux, C; Liesveld, J; Lopez, PF; Radinoff, A; Sangerman, MA; Sekeres, MA; Selleslag, D; Tzvetkov, N; Watts, J; Zeidner, JF; Zhao, D | 1 |
| Bowen, S; Dai, Y; Faller, DV; Friedlander, S; Haikawa, K; Hua, Z; Kupperman, E; Kuroda, S; Nakai, K; Sedarati, F; Venkatakrishnan, K; Yamamoto, Y; Yuan, Y; Zhou, X | 1 |
3 trial(s) available for cyclopentane and Leukemia, Myelomonocytic, Chronic
| Article | Year |
|---|---|
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Drug Therapy, Combination; Humans; Leukemia, Myelomonocytic, Chronic; Pyrimidines | 2022 |
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cyclopentanes; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Pyrimidines | 2021 |
Asia-inclusive global development of pevonedistat: Clinical pharmacology and translational research enabling a phase 3 multiregional clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Azacitidine; Cyclopentanes; Drugs, Investigational; Global Burden of Disease; Humans; Incidence; International Cooperation; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Maximum Tolerated Dose; Myelodysplastic Syndromes; Pharmacology, Clinical; Pyrimidines; Translational Research, Biomedical; Ubiquitin-Activating Enzymes; United States | 2021 |